Clinton and GOP hopeful Donald Trump support the right for the government to negotiate Medicare drug costs. Additionally, Clinton has previously stated she would tackle “price gouging” from drugmakers if she is elected.
Related: Healthcare ETFs Ready to Rally
On Thursday, IBB “hit a high of $300.29 Thursday, and closed at $300.08, just below the $302.40 level hit in January. The previously elusive $300 mark has been a level of resistance for the ETF, which tested that level twice in August before trading lower,” according to CNBC.
The overall pharmaceutical industry has also taken a greater interest in so-called orphan drugs due to their strong protection, which helps support reliable pricing power, especially as the industry faces questions over high pricing over primary care products.
For more information on the biotech sector, visit our biotechnology category.